ArticleJournal of diabetes research2016
Protective Effects of Celastrol on Diabetic Liver Injury via TLR4/MyD88/NF-κB Signaling Pathway in Type 2 Diabetic Rats.
Article in Journal of diabetes research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Alterations in Immune Cell Profiles in the Liver in Diabetes Mellitus: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Metformin-phytochemical combination therapy in metabolic dysfunction-associated steatotic liver disease: mechanistic insights and therapeutic potential.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Therapeutic effects of vitamin D and intermittent fasting on metabolic associated steatotic liver disease in rats.Scientific reports · 2026Article
- The role of celastrol in inflammation and diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Targeting the TLR4 axis with microbiota-oriented interventions and innovations in diabetes therapy: a narrative review.Frontiers in immunology · 2025Review
- Role of long non-coding RNA in inflammatory bowel disease.Frontiers in immunology · 2024Review
- Celastrol Treatment Ameliorated Acute Ischemic Stroke-Induced Brain Injury by Microglial Injury Inhibition and Nrf2/HO-1 Pathway Activations.BioMed research international · 2023Article
- Stellate ganglion block reduces inflammation and improves neurological function in diabetic rats during ischemic stroke.Neural regeneration research · 2022Article
- Analysis of circRNA-mRNA expression profiles and functional enrichment in diabetes mellitus based on high throughput sequencing.International wound journal · 2022Article
- Therapeutic Potential of Allicin and Aged Garlic Extract in Alzheimer's Disease.International journal of molecular sciences · 2022Review
- Celastrol attenuates the remodeling of pulmonary vascular and right ventricular in monocrotaline-induced pulmonary arterial hypertension in rats.Cardiovascular diagnosis and therapy · 2022Article
- Celastrol attenuates chronic constrictive injury-induced neuropathic pain and inhibits the TLR4/NF-κB signaling pathway in the spinal cord.Journal of natural medicines · 2022Article
- Allicin, an Antioxidant and Neuroprotective Agent, Ameliorates Cognitive Impairment.Antioxidants (Basel, Switzerland) · 2021Review
- Celastrol-based nanomedicine promotes corneal allograft survival.Journal of nanobiotechnology · 2021Article
- Celastrol inhibits the proliferation and angiogenesis of high glucose-induced human retinal endothelial cells.Biomedical engineering online · 2021Article
- Nutritional Effects of the Enteral Nutritional Formula on Regulation of Gut Microbiota and Metabolic Level in Type 2 Diabetes Mellitus Mice.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Synergistic anti-liver cancer effects of curcumin and total ginsenosides.World journal of gastrointestinal oncology · 2020Article
- TLR4 contributes to the damage of cartilage and subchondral bone in discectomy-induced TMJOA mice.Journal of cellular and molecular medicine · 2020Article
- Overexpressed microRNA-494 represses RIPK1 to attenuate hippocampal neuron injury in epilepsy rats by inactivating the NF-κB signaling pathway.Cell cycle (Georgetown, Tex.) · 2020Article
- Celastrol Alleviates Gamma Irradiation-Induced Damage by Modulating Diverse Inflammatory Mediators.International journal of molecular sciences · 2020Article
Corrections and comments
- Retracted
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune and inflammatory pathways play a central role in the pathogenesis of diabetic liver injury. Celastrol is a potent immunosuppressive and anti-inflammatory agent. So far, there is no evidence regarding the mechanism of innate immune alterations of celastrol on diabetic liver injury in type 2 diabetic animal models. The present study was aimed at investigating protective effects of celastrol on the liver injury in diabetic rats and at elucidating the possible involved mechanisms. We analyzed the liver histopathological and biochemical changes and the expressions of TLR4 mediated signaling pathway. Compared to the normal control group, diabetic rats were found to have obvious steatohepatitis and proinflammatory cytokine activities were significantly upregulated. Celastrol-treated diabetic rats show reduced hepatic inflammation and macrophages infiltration. The expressions of TLR4, MyD88, NF-κB, and downstream inflammatory factors IL-1β and TNFα in the hepatic tissue of treated rats were downregulated in a dose-dependent manner. We firstly found that celastrol treatment could delay the progression of diabetic liver disease in type 2 diabetic rats via inhibition of TLR4/MyD88/NF-κB signaling cascade pathways and its downstream inflammatory effectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.